D
iBio, Inc.
IBIO
$4.86
-$0.22-4.33%
D
Sell
2/19/2025Upgraded
iBio, Inc. (IBIO) was upgraded to D- from E+ on 2/19/2025 due to a noticeable increase in the total return index, volatility index and solvency index.
iBio, Inc. (IBIO) was upgraded to D- from E+ on 2/19/2025 due to a noticeable increase in the total return index, volatility index and solvency index.
E
Sell
12/30/2024Downgrade
iBio, Inc. (IBIO) was downgraded to E+ from D- on 12/30/2024 due to a decline in the volatility index.
iBio, Inc. (IBIO) was downgraded to E+ from D- on 12/30/2024 due to a decline in the volatility index.
D
Sell
12/13/2024Upgraded
iBio, Inc. (IBIO) was upgraded to D- from E+ on 12/13/2024 due to an increase in the growth index, solvency index and volatility index. Earnings per share increased from -$0.9062 to -$0.4621, and operating cash flow increased 23.47% from -$4.85M to -$3.72M.
iBio, Inc. (IBIO) was upgraded to D- from E+ on 12/13/2024 due to an increase in the growth index, solvency index and volatility index. Earnings per share increased from -$0.9062 to -$0.4621, and operating cash flow increased 23.47% from -$4.85M to -$3.72M.
E
Sell
10/24/2024Downgrade
iBio, Inc. (IBIO) was downgraded to E+ from D- on 10/24/2024 due to a decline in the volatility index.
iBio, Inc. (IBIO) was downgraded to E+ from D- on 10/24/2024 due to a decline in the volatility index.
D
Sell
10/8/2024Upgraded
iBio, Inc. (IBIO) was upgraded to D- from E+ on 10/8/2024 due to a major increase in the growth index, solvency index and volatility index. The quick ratio increased from 0.91 to 3.7, debt to equity declined from 0.6 to 0.09, and EBIT increased 5.98% from -$3.63M to -$3.41M.
iBio, Inc. (IBIO) was upgraded to D- from E+ on 10/8/2024 due to a major increase in the growth index, solvency index and volatility index. The quick ratio increased from 0.91 to 3.7, debt to equity declined from 0.6 to 0.09, and EBIT increased 5.98% from -$3.63M to -$3.41M.
E
Sell
12/6/2022Downgrade
iBio, Inc. (IBIO) was downgraded to E+ from D- on 12/6/2022 due to a noticeable decline in the solvency index, volatility index and growth index. The quick ratio declined from 1.13 to 0.58, debt to equity increased from 0.35 to 0.47, and operating cash flow declined 21.35% from -$11.5M to -$13.96M.
iBio, Inc. (IBIO) was downgraded to E+ from D- on 12/6/2022 due to a noticeable decline in the solvency index, volatility index and growth index. The quick ratio declined from 1.13 to 0.58, debt to equity increased from 0.35 to 0.47, and operating cash flow declined 21.35% from -$11.5M to -$13.96M.
D
Sell
10/12/2022Downgrade
iBio, Inc. (IBIO) was downgraded to D- from D on 10/12/2022 due to a major decline in the growth index and solvency index. Total revenue declined 96.86% from $1.94M to $61, operating cash flow declined 93.52% from -$5.94M to -$11.5M, and the quick ratio declined from 5.99 to 1.13.
iBio, Inc. (IBIO) was downgraded to D- from D on 10/12/2022 due to a major decline in the growth index and solvency index. Total revenue declined 96.86% from $1.94M to $61, operating cash flow declined 93.52% from -$5.94M to -$11.5M, and the quick ratio declined from 5.99 to 1.13.
D
Sell
5/16/2022Upgraded
iBio, Inc. (IBIO) was upgraded to D from E+ on 5/16/2022 due to an increase in the total return index, volatility index and valuation index.
iBio, Inc. (IBIO) was upgraded to D from E+ on 5/16/2022 due to an increase in the total return index, volatility index and valuation index.
E
Sell
5/13/2022Downgrade
iBio, Inc. (IBIO) was downgraded to E+ from D on 05/13/2022.
iBio, Inc. (IBIO) was downgraded to E+ from D on 05/13/2022.
D
Sell
5/4/2022Upgraded
iBio, Inc. (IBIO) was upgraded to D from E+ on 5/4/2022 due to an increase in the total return index.
iBio, Inc. (IBIO) was upgraded to D from E+ on 5/4/2022 due to an increase in the total return index.
E
Sell
5/1/2022Downgrade
iBio, Inc. (IBIO) was downgraded to E+ from D on 05/01/2022.
iBio, Inc. (IBIO) was downgraded to E+ from D on 05/01/2022.
D
Sell
4/21/2022Upgraded
iBio, Inc. (IBIO) was upgraded to D from E+ on 4/21/2022 due to an increase in the total return index and valuation index.
iBio, Inc. (IBIO) was upgraded to D from E+ on 4/21/2022 due to an increase in the total return index and valuation index.
E
Sell
4/20/2022Downgrade
iBio, Inc. (IBIO) was downgraded to E+ from D on 4/20/2022 due to a substantial decline in the total return index, volatility index and solvency index. Debt to equity increased from 0.01 to 0.25, and the quick ratio declined from 10.19 to 6.89.
iBio, Inc. (IBIO) was downgraded to E+ from D on 4/20/2022 due to a substantial decline in the total return index, volatility index and solvency index. Debt to equity increased from 0.01 to 0.25, and the quick ratio declined from 10.19 to 6.89.
D
Sell
11/22/2021Upgraded
iBio, Inc. (IBIO) was upgraded to D from D- on 11/22/2021 due to an increase in the total return index, volatility index and valuation index.
iBio, Inc. (IBIO) was upgraded to D from D- on 11/22/2021 due to an increase in the total return index, volatility index and valuation index.
D
Sell
11/8/2021Downgrade
iBio, Inc. (IBIO) was downgraded to D- from D on 11/8/2021 due to a decline in the valuation index.
iBio, Inc. (IBIO) was downgraded to D- from D on 11/8/2021 due to a decline in the valuation index.
D
Sell
5/1/2020Upgraded
iBio, Inc. (IBIO) was upgraded to D from D- on 5/1/2020 due to a major increase in the total return index and volatility index.
iBio, Inc. (IBIO) was upgraded to D from D- on 5/1/2020 due to a major increase in the total return index and volatility index.
D
Sell
1/6/2020Upgraded
iBio, Inc. (IBIO) was upgraded to D- from E+ on 1/6/2020 due to an increase in the volatility index.
iBio, Inc. (IBIO) was upgraded to D- from E+ on 1/6/2020 due to an increase in the volatility index.
E
Sell
12/19/2019Downgrade
iBio, Inc. (IBIO) was downgraded to E+ from D- on 12/19/2019 due to a decline in the volatility index and total return index.
iBio, Inc. (IBIO) was downgraded to E+ from D- on 12/19/2019 due to a decline in the volatility index and total return index.
D
Sell
12/4/2019Upgraded
iBio, Inc. (IBIO) was upgraded to D- from E+ on 12/4/2019 due to an increase in the growth index and volatility index. Operating cash flow increased 47.93% from -$4.39M to -$2.29M, earnings per share increased from -$0.2294 to -$0.2066, and EBIT increased 0.49% from -$3.87M to -$3.86M.
iBio, Inc. (IBIO) was upgraded to D- from E+ on 12/4/2019 due to an increase in the growth index and volatility index. Operating cash flow increased 47.93% from -$4.39M to -$2.29M, earnings per share increased from -$0.2294 to -$0.2066, and EBIT increased 0.49% from -$3.87M to -$3.86M.
E
Sell
11/5/2019Downgrade
iBio, Inc. (IBIO) was downgraded to E+ from D- on 11/5/2019 due to a decline in the solvency index, efficiency index and volatility index. Debt to equity increased from 0.03 to 0.09, the quick ratio declined from 2.26 to 1.31, and total capital declined 14.12% from $31.84M to $27.34M.
iBio, Inc. (IBIO) was downgraded to E+ from D- on 11/5/2019 due to a decline in the solvency index, efficiency index and volatility index. Debt to equity increased from 0.03 to 0.09, the quick ratio declined from 2.26 to 1.31, and total capital declined 14.12% from $31.84M to $27.34M.
D
Sell
9/19/2018Upgraded
iBio, Inc. (IBIO) was upgraded to D- from E+ on 9/19/2018 due to an increase in the growth index, solvency index and valuation index. The quick ratio increased from 1.84 to 7.87, debt to equity declined from 0.05 to 0.01, and total revenue increased 16.67% from $78 to $91.
iBio, Inc. (IBIO) was upgraded to D- from E+ on 9/19/2018 due to an increase in the growth index, solvency index and valuation index. The quick ratio increased from 1.84 to 7.87, debt to equity declined from 0.05 to 0.01, and total revenue increased 16.67% from $78 to $91.
E
Sell
5/11/2018Downgrade
iBio, Inc. (IBIO) was downgraded to E+ from D- on 5/11/2018 due to a decline in the valuation index and solvency index. Debt to equity increased from 0.02 to 0.05, and the quick ratio declined from 3.64 to 1.84.
iBio, Inc. (IBIO) was downgraded to E+ from D- on 5/11/2018 due to a decline in the valuation index and solvency index. Debt to equity increased from 0.02 to 0.05, and the quick ratio declined from 3.64 to 1.84.
D
Sell
3/7/2018Upgraded
iBio, Inc. (IBIO) was upgraded to D- from E+ on 3/7/2018 due to an increase in the volatility index and solvency index. Debt to equity declined from 0.03 to 0.02, and the quick ratio increased from 2.93 to 3.64.
iBio, Inc. (IBIO) was upgraded to D- from E+ on 3/7/2018 due to an increase in the volatility index and solvency index. Debt to equity declined from 0.03 to 0.02, and the quick ratio increased from 2.93 to 3.64.
E
Sell
2/12/2018Downgrade
iBio, Inc. (IBIO) was downgraded to E+ from D- on 2/12/2018 due to a major decline in the total return index, volatility index and efficiency index. Total capital declined 7.8% from $34.18M to $31.51M.
iBio, Inc. (IBIO) was downgraded to E+ from D- on 2/12/2018 due to a major decline in the total return index, volatility index and efficiency index. Total capital declined 7.8% from $34.18M to $31.51M.
D
Sell
1/9/2017Downgrade
iBio, Inc. (IBIO) was downgraded to D- from D on 1/9/2017 due to a major decline in the solvency index, total return index and volatility index. The quick ratio declined from 10.31 to 9.35.
iBio, Inc. (IBIO) was downgraded to D- from D on 1/9/2017 due to a major decline in the solvency index, total return index and volatility index. The quick ratio declined from 10.31 to 9.35.
D
Sell
5/24/2016Upgraded
iBio, Inc. (IBIO) was upgraded to D from D- on 5/24/2016 due to an increase in the efficiency index, total return index and volatility index. Total capital increased 514.25% from $7.88M to $48.39M.
iBio, Inc. (IBIO) was upgraded to D from D- on 5/24/2016 due to an increase in the efficiency index, total return index and volatility index. Total capital increased 514.25% from $7.88M to $48.39M.
D
Sell
3/11/2016Downgrade
iBio, Inc. (IBIO) was downgraded to D- from D on 3/11/2016 due to a large decline in the growth index, volatility index and efficiency index. Operating cash flow declined 45.34% from -$1.15M to -$1.67M, earnings per share declined from -$0.0233 to -$0.029, and net income declined 24.43% from -$1.81M to -$2.25M.
iBio, Inc. (IBIO) was downgraded to D- from D on 3/11/2016 due to a large decline in the growth index, volatility index and efficiency index. Operating cash flow declined 45.34% from -$1.15M to -$1.67M, earnings per share declined from -$0.0233 to -$0.029, and net income declined 24.43% from -$1.81M to -$2.25M.
NASDAQ
03/17/2025 4:00PM Eastern
Quotes delayed
